Ally Bridge Group — 2018 Investments

3 investments dated 2018 · listed companies and verified rows first · show all

Grailgrail.com in 𝕏NASDAQ: GRALMay 2018

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)

Co-investorsAmino Capital ARCH Venture Partners Bezos Expeditions Bluebird Ventures Decheng Capital Dentsu Ventures +13 more

Epicrispr Biotechnologiesepicrispr.com in 𝕏May 2018

Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)

BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)

Co-investorsSanofi Ventures Angelini Ventures Fidelity Investments Janus Henderson Investors

Hua Medicinehuamedicine.comMar 2018 · $117.4M

Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.

Li Chen(Founder)

Co-investorsARCH Venture Partners F-Prime Capital Venrock 6 Dimensions Capital Blue Pool Capital Eight Roads Ventures +2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.